retatrutide type 2 diabetes phase 2 results 2024 produces up to 30.3% weight loss in 3 trial Retatrutide—A Game Changer in Obesity

Foundayo (orforglipron) is Eli Lilly's small-molecule oral GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity or overweight with a weight-related condition

Record previous implants, scars, or clotting issues

Does Microdosing Curb Appetite

GLP-1 Examples Patients often seek clarity regarding available GLP-1 medications

Inject subcutaneously at a 90-degree angle, holding the pen in place for the recommended duration (varies by product, typically 610 seconds) to ensure full dose delivery

In addition to gastroparesis, Ozempic users have reported other serious side effects